Baird Downgrades Inari Medical to Neutral, Lowers Price Target to $80

Benzinga · 01/07 10:18
Baird analyst David Rescott downgrades Inari Medical (NASDAQ:NARI) from Outperform to Neutral and lowers the price target from $81 to $80.